<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2114">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133635</url>
  </required_header>
  <id_info>
    <org_study_id>Steroid/Toci COVID-19</org_study_id>
    <nct_id>NCT05133635</nct_id>
  </id_info>
  <brief_title>High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19</brief_title>
  <official_title>Comparison of the Treatment Efficacy of High-Dose Corticosteroid and Tocilizumab During Clinical Worsening in Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marmara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 pandemic has spread all over the world, and hospitalization of the patients with&#xD;
      COVÄ°D-19 Pneumonia has become a great burden to the Intensive Care Units. Unfortunately there&#xD;
      is still no curative method for the disease yet. Intensive Care Units provide general care&#xD;
      for the patients; including oxygen therapy, maintenance of the organ systems (e.g.,&#xD;
      cardiovascular, renal), nutrition, antibiotic therapy for secondary infections, and etc.&#xD;
&#xD;
      One of the major problems in COVID-19 is macrophage activation syndrome, also known as&#xD;
      cytokine storm. It stems from exaggerated inflammatory response, which causes increased&#xD;
      cytokine release and results in clinical deterioration of the patients. Many drugs have been&#xD;
      used to prevent this exaggerated inflammation, like corticosteroids, interleukin (IL)&#xD;
      receptor blockers, plasma exchange, etc.&#xD;
&#xD;
      In this study our aim is to investigate the effectiveness of high dose corticosteroid&#xD;
      (methylprednisolone 250 mg for 3 days) and an IL-6 receptor antagonist (tocilizumab) in the&#xD;
      treatment of the cytokine storm of the COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    A recent study suggested a new corticosteroid regime for intensive care unit patients.&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical condition</measure>
    <time_frame>Next 7 days of the intervention.</time_frame>
    <description>Arterial oxygen partial pressure of the patient will be observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood analysis</measure>
    <time_frame>Next 7 days of the intervention.</time_frame>
    <description>Acute phase reactants (C-reactive protein, procalcitonin, ferritin, fibrinogen), will be investigated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Until the hospital discharge.</time_frame>
    <description>Hospital stay period of the patients will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Not relevant</time_frame>
    <description>Mortality of the patients will be observed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19 Virus Infection</condition>
  <condition>Cytokine Storm</condition>
  <condition>Corticosteroid</condition>
  <condition>Tocilizumab</condition>
  <arm_group>
    <arm_group_label>Pulse methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg methylprednisolone for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tocilizumab 400-800 mg for one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.</description>
    <arm_group_label>Pulse methylprednisolone</arm_group_label>
    <other_name>Corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with COVID-19 Pneumonia treated in the Intensive Care Unit&#xD;
&#xD;
          -  Clinical deterioration during intensive care follow-up&#xD;
&#xD;
          -  First 14 days from the COVID-19 diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 14 days passed from the COVID-19 diagnosis&#xD;
&#xD;
          -  Clinical and laboratory signs of secondary bacterial infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruslan Abdullayev</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marmara University</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marmara University</investigator_affiliation>
    <investigator_full_name>Ruslan Abdullayev</investigator_full_name>
    <investigator_title>Assist. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

